Neovasc Inc.

Recent News

  • Shockwave Medical to Acquire Neovasc

    Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Company (the "Transaction").Under the terms of the Arrangement...

    2023-01-17 8:27 AM EST
  • Neovasc Announces Progress on COSIRA-II Clinical Trial

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patients at up to 50 sites in North America. To...

    2022-11-28 5:00 PM EST
  • Neovasc Comments on European Heart Journal Publication

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart Journal - Case Reports has published an article titled, "Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy - a Case Report." The article is authored by Dr. Kevin Cheng, et al, at the National Heart and Lung Institute Imperial College London, Royal...

    2022-11-18 9:05 AM EST
  • Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2022.Recent HighlightsGenerated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021.Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter.Continued enrollment in the COSIRA II pivotal trial, with...

    2022-11-10 4:05 PM EST
  • Neovasc Reducer Obtains U.S. Outpatient Reimbursement

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reducer") implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.Effective January 1, 2023, the implantation of the Reducer in an outpatient setting is assigned to Healthcare Common Procedure Coding System...

    2022-11-08 9:05 AM EST
  • Neovasc to Report Third Quarter Financial Results on November 10, 2022

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022.Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International)...

    2022-10-27 9:00 AM EDT
  • Neovasc Provides Corporate Update Following Clinical Data Release

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 20, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference ("TCT") held September 16-19 in Boston.Prof. Shmuel Banai, MD, Neovasc Medical Director and Head of Interventional Cardiology at the Tel Aviv Medical Center, Israel, presented new interim clinical data on the use of the Neovasc Reducer™ ("Reducer") in patients who have angina with non-obstructive coronary artery disease, so-called...

    2022-09-20 9:05 AM EDT
  • Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 11:10 am BST / 6:10 am ET on September 23, 2022. Interested parties may view a live stream of Mr. Colen's presentation by registering on...

    2022-09-16 9:00 AM EDT